This year the CDISC Glossary update included a more robust and frequently used request process for new terms because the Glossary activity was better integrated into the CDISC Controlled Terminology Team that supports the exchange of digital information. The Glossary seeks to eliminate semantic confusion in human information exchange and disambiguate the meaning of terms, acronyms, abbreviations, and initials used in the various foundational standards developed by CDISC for clinical research. The Glossary also serves as an educational resource for the clinical research community, by defining relevant terms pertaining to clinical research, including eClinical investigations, sponsored by the pharmaceutical industry or a federal agency. The team updated about 50 existing terms; reviewed close to 100 new terms that had been proposed; and updated or added more than 150 Acronyms/Abbreviations/Initials not included last year. In addition, sources for definitions from new guidelines are provided in the Glossary.xls format as a tab for ease of use.
Download Statistics for the Glossary publication files from the NCI FTP site from public review month to November
To complete the 2018 expansion of the published 2017 CDISC Glossary, the team met every week virtually; held a two-day face-to-face workshop of intensive team review and preparation of related-term clusters that would be useful to a user to consider as a group; and prepared the Glossary for annual public review in September. Terms that fit the new concept of definition “clusters” were monitoring, exposure, study participant/subject, investigator, just to give a few examples.
All formats of the updated Glossary, the Glossary directory, the New Term request form are available at:
https://www.cancer.gov/research/resources/terminology/cdisc
CDISC Glossary Team members are:
Helle Gawrylewski as Lead, Guido Claes, and Denise Adelman (all Janssen R&D of J&J); Erin Muhlbradt (EVS in NCI/NIH); Art Gertel (MedSciCom); Stephen Raymond (ERT); Jon Hilton (F. Hoffmann-La Roche Ltd); Chris Gemma (CDISC); and Melissa Cook (MC Consulting).
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.